Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): Some feel the news leak that Bristol-Myers Squibb (NYSE:BMY) made a bid for Amylin (NASDAQ:AMLN) may have been to put the “kibosh” on any efforts by Amylin to form a partnership to help market Bydureon outside the U.S. Partnerships make small drug makers less attractive to big firms looking for acquisitions. Barron’s contends the best way to manage risk and reward is to keep a position, if one is owned, and to lock in some profits. The shares closed at $23.77, up $8.38, or 54.45%. They have traded in a 52-week range of $8.03 to $18.45.
Pentair, Inc. (NYSE:PNR): Pentair CEO sees higher growth for combined Pentair/Tyco Flow.
Hogan says deal is a “growth” effort, not a plant consolidation one. Pentair CEO Randall Hogan speaking on CNBC. The shares closed at $46.32, up $6.06, or 15.05%. They have traded in a 52-week range of $29.73 to $42.43.
KiOR Inc (NASDAQ:KIOR): Cowen said KiOR’s Q4 results were in-line with expectations. The firm still sees upside to the shares citing construction of its first plant ahead of construction and a second site already planned. Cowen said KiOR set conservative expectations but has improved R&D in several areas pointing to long-term improvement on yield expectations. Shares are Outperform rated. The shares closed at $13.51, up $1.05, or 8.43%. They have traded in a 52-week range of $7.51 to $23.85.
Robbins & Myers, Inc. (NYSE:RBN): Reported Q2 revenue $256M versus consensus $238.26M. The shares closed at $50.81, up $4.98, or 10.87%. They have traded in a 52-week range of $31.54 to $55.63.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com